“Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycemic control in patient with type 2 diabetes mellitus”

Abstract:

The aim of the present study is to compare the effect of metformin in combination
with Glimepiride and Glibenclamide In patient with type 2 Diabetes Mellitus.
Subjects and method: This is an open-label, randomized study carried out to study the
effect of metformin when it is given in combination with either glimepiride or
glibenclamide on glycaemic control in patient with type 2 Diabetes Mellitus. Patients
with Glycosylated Hemoglobin more than 7% were included in the study. 31 patients
were randomly assigned for treatment based on metformin-glibenclamide 1000/10 mg
tablets or metformin-glimepiride1000/2mg for 12 weeks. The comparisons were
conducted between these two groups for HbA1C, FPG, PPG and lipid profile. Result:
At week 12, the significant reductions in HbA1c were found in both groups but the
patients treated with metformin-glimepiride resulted in significantly greater
reductions in HbA1C (-1.4%) than metformin-glibenclamide (-1.2%). Also the greater
significant reductions were observed in case of FPG, total cholesterole, serum
triglyceride and LDL cholesterole in patient with metformin-glimepiride group.
Conclusion: Metformin-glimepiride tablets resulted in significantly greater reductions
in HbA1C and fasting plasma glucose compared with metformin plus glibenclamide in
patients with type 2 diabetes mellitus.
Keywords: combination therapy, glimepiride, glibenclamide, metformin, type 2
diabetes mellitus.